Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Primary pulmonary hypertension.

Literature DB >> 8325077

Primary pulmonary hypertension.

L J Rubin.

Abstract

Entities: Disease

Mesh：

Year: 1993 PMID： 8325077 DOI： 10.1378/chest.104.1.236

Source DB: PubMed Journal: Chest ISSN： 0012-3692 Impact factor: 9.410

Keyword Cloud
Cited

× No keyword cloud information.

41 in total

Review 1. Primary pulmonary hypertension: the pressure rises for a gene.

Authors: J R Thomson; R C Trembath
Journal: J Clin Pathol Date: 2000-12 Impact factor: 3.411

2. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.

Authors: Brooke Harrison; Mindy H Magee; Arun Mandagere; Gennyne Walker; Christopher Dufton; Linda S Henderson; Ramesh Boinpally
Journal: Clin Drug Investig Date: 2010 Impact factor: 2.859

3. International Classification of Diseases coding changes lead to profound declines in reported idiopathic pulmonary arterial hypertension mortality and hospitalizations: implications for database studies.

Authors: Jeffrey Link; Craig Glazer; Fernando Torres; Kelly Chin
Journal: Chest Date: 2010-08-19 Impact factor: 9.410

4. Exercise-induced pulmonary artery hypertension in a patient with compensated cardiac disease: hemodynamic and functional response to sildenafil therapy.

Authors: Lazaros Nikolaidis; Nabeel Memon; Brian O'Murchu
Journal: Tex Heart Inst J Date: 2015-02-01

5. Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome.

Authors: Nili Zafrir; Boris Zingerman; Alejandro Solodky; Daniel Ben-Dayan; Alex Sagie; Jaqueline Sulkes; Israel Mats; M R Kramer
Journal: Int J Cardiovasc Imaging Date: 2006-09-14 Impact factor: 2.357

6. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing.

Authors: John H Wlodarczyk; Leslie G Cleland; Anne M Keogh; Keith D McNeil; Kate Perl; Robert G Weintraub; Trevor J Williams
Journal: Pharmacoeconomics Date: 2006 Impact factor: 4.981

Primary pulmonary hypertension.

Review 1. Primary pulmonary hypertension: the pressure rises for a gene.

2. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.

3. International Classification of Diseases coding changes lead to profound declines in reported idiopathic pulmonary arterial hypertension mortality and hospitalizations: implications for database studies.

4. Exercise-induced pulmonary artery hypertension in a patient with compensated cardiac disease: hemodynamic and functional response to sildenafil therapy.

5. Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome.

6. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing.

7. Sildenafil--a possible treatment for acute pulmonary hypertension during cardiac surgery.

8. Pulmonary hypertension--a new manifestation of mitochondrial disease.

9. The cancer paradigm of severe pulmonary arterial hypertension.

Review 10. Primary pulmonary hypertension associated with human immunodeficiency virus infection.